Answers are grounded in this paper and cite their sources.
Activating RAS mutations drive a substantial proportion of human cancers, yet for decades RAS was considered undruggable. The recent development of tri-complex inhibitors (TCIs) such as daraxonrasib (RMC-6236) has transformed the therapeutic landscape by enabling potent, multi-selective targeting of the active, GTP-bound state of multiple RAS isoforms. This review synthesizes preclinical and clinical evidence on daraxonrasib and related RAS(ON) inhibitors across RAS-mutant malignancies, including pancreatic ductal adenocarcinoma, non-small cell lung cancer, colorectal cancer, melanoma, and cholangiocarcinoma. We examine the structural basis of TCI action, pharmacokinetic considerations, and the profound tumor regressions observed in early-phase trials, including the unprecedented overall survival benefit in PDAC. A central focus is the emergence of resistance through diverse mechanisms: acquired mutations in CYPA, RAS, and BRAF that disrupt drug-target complex formation or restore RAS-RAF signaling; adaptive rewiring via mTORC1, STAT3, and cell cycle pathways; and tumor microenvironment-mediated resistance. We further explore rational combination strategies designed to forestall resistance, including vertical MAPK pathway blockade, orthogonal inhibition of EGFR/STAT3, CDK4/6 targeting, and immunotherapy combinations that leverage RAS inhibition-induced immune priming. By integrating structural biology, translational pharmacology, and clinical outcomes, this review provides a comprehensive framework for understanding the promise and challenges of pan-RAS inhibition in precision oncology.
No takes yet. Share an insight, caveat, or question.
Lou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: